Factors contributing to the immunogenicity of meningococcal conjugate vaccines

Synthesis and immunological study of α-2,9-oligosialic acid conjugates as anti-group C meningitis vaccines

(2015) Guochao Liao et al.   CHEMICAL COMMUNICATIONS

Thimerosal: Clinical, epidemiologic and biochemical studies

(2015) David A. Geier et al.   CLINICA CHIMICA ACTA

Technical Development of a New Meningococcal Conjugate Vaccine

(2015) Carl E. Frasch et al.   CLINICAL INFECTIOUS DISEASES

MenAfriVac as an Antitetanus Vaccine

(2015) Ray Borrow et al.   CLINICAL INFECTIOUS DISEASES

Development and characterization of Haemophilus influenzae type b conjugate vaccine prepared using different polysaccharide chain lengths

(2015) R. Rana et al.   VACCINE

Influence of elemental impurities in aluminum hydroxide adjuvant on the stability of inactivated Japanese Encephalitis vaccine, IXIARO®

(2015) Robert Schlegl et al.   VACCINE

Carrier priming with CRM197 or diphtheria toxoid has a different impact on the immunogenicity of the respective glycoconjugates: Biophysical and immunochemical interpretation

(2015) S. Pecetta et al.   VACCINE

Structural correlates of carrier protein recognition in tetanus toxoid-conjugated bacterial polysaccharide vaccines

(2015) Kay Lockyer et al.   VACCINE

Conjugation of β-glucan markedly increase the immunogencity of meningococcal group Y polysaccharide conjugate vaccine

(2015) Weilin Qiao et al.   VACCINE

Synthesis and immunological evaluation of protein conjugates ofNeisseria meningitidisX capsular polysaccharide fragments

(2014) Laura Morelli et al.   Beilstein Journal of Organic Chemistry

Process development and immunogenicity studies on a serogroup ‘X’ Meningococcal polysaccharide conjugate vaccine

(2014) Srinivas Reddy Chilukuri et al.   BIOLOGICALS

Glycoconjugate vaccines: an update

(2014) Mairi Vella et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Meningococcal serogroup A and tetanus immunity two years after MenAfriVac™ introduction in Mali

(2014) N.E. Basta et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Carrier priming or suppression: Understanding carrier priming enhancement of anti-polysaccharide antibody response to conjugate vaccines

(2014) Karl Pobre et al.   VACCINE

Antitoxins for diphtheria and tetanus decline more slowly after vaccination with DTwP than with DTaP: A study in a Chinese population

(2014) Yuyan Wu et al.   VACCINE

Synthesis ofNeisseria meningitidisSerogroup W135 Capsular Oligosaccharides for Immunogenicity Comparison and Vaccine Development

(2013) Chia-Hung Wang et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Meningococcal Polysaccharide AO-Acetylation Levels Do Not Impact the Immunogenicity of the Quadrivalent Meningococcal Tetanus Toxoid Conjugate Vaccine: Results from a Randomized, Controlled Phase III Study of Healthy Adults Aged 18 to 25 Years

(2013) Socorro Lupisan et al.   Clinical and Vaccine Immunology

Immunogenicity and Safety of a Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine (MenACWY-TT) Administered to Adults Aged 56 Years and Older: Results of an Open-Label, Randomized, Controlled Trial

(2013) Ghassan Dbaibo et al.   DRUGS & AGING

Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2–10-year-old children: results of an open, randomised, controlled study

(2013) Markus Knuf et al.   EUROPEAN JOURNAL OF PEDIATRICS

Functional expression of the capsule polymerase of Neisseria meningitidis serogroup X: A new perspective for vaccine development

(2013) T. Fiebig et al.   GLYCOBIOLOGY

PEG as a spacer arm markedly increases the immunogenicity of meningococcal group Y polysaccharide conjugate vaccine

(2013) Qingrui Huang et al.   JOURNAL OF CONTROLLED RELEASE

Key roles of adjuvants in modern vaccines

(2013) Steven G Reed et al.   NATURE MEDICINE

Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X

(2013) F. Micoli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Comparison of CRM197, diphtheria toxoid and tetanus toxoid as protein carriers for meningococcal glycoconjugate vaccines

(2013) M. Tontini et al.   VACCINE

Effect of Increased CRM197Carrier Protein Dose on Meningococcal C Bactericidal Antibody Response

(2012) Lucia H. Lee et al.   Clinical and Vaccine Immunology

Immunogenicity of a Single Dose of Meningococcal Group C Conjugate Vaccine Given at 3 Months of Age to Healthy Infants in the United Kingdom

(2012) Helen Findlow et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Immunogenicity and Safety of a Booster Dose of the 10-valent Pneumococcal Haemophilus Influenzae Protein D Conjugate Vaccine Coadministered With the Tetravalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine in Toddlers

(2012) Guillermo M. Ruiz-Palacios et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197

(2012) E. Malito et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Development of a group A meningococcal conjugate vaccine,MenAfriVacTM

(2012) Carl Frasch et al.   Human Vaccines & Immunotherapeutics

Biochemical and biological characteristics of cross-reacting material 197 (CRM197), a non-toxic mutant of diphtheria toxin: Use as a conjugation protein in vaccines and other potential clinical applications

(2011) Michael Bröker et al.   BIOLOGICALS

Concomitant Administration of Mycobacterium bovis BCG with the Meningococcal C Conjugate Vaccine to Neonatal Mice Enhances Antibody Response and Protective Efficacy

(2011) Siggeir F. Brynjolfsson et al.   Clinical and Vaccine Immunology

MF59 adjuvant: the best insurance against influenza strain diversity

(2011) Derek T O’Hagan et al.   Expert Review of Vaccines

Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules

(2011) Ray Borrow et al.   Expert Review of Vaccines

A Randomized Trial to Assess Safety and Immunogenicity of Alternative Formulations of a Quadrivalent Meningococcal (A, C, Y, and W-135) Tetanus Protein Conjugate Vaccine in Toddlers

(2011) Jodie McVernon et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Effect of thiomersal on dissociation of intact (146S) foot-and-mouth disease virions into 12S particles as assessed by novel ELISAs specific for either 146S or 12S particles

(2011) M.M. Harmsen et al.   VACCINE

Comparative effects of carrier proteins on vaccine-induced immune response

(2011) Markus Knuf et al.   VACCINE

High tetanus antitoxin antibody concentrations in the Netherlands: A seroepidemiological study

(2010) Anneke Steens et al.   VACCINE

Overview of the development and current use of CRM197 conjugate vaccines for pediatric use

(2010) Henry R. Shinefield   VACCINE

Glycoconjugate vaccines and immune interference: A review

(2010) Ron Dagan et al.   VACCINE

Conformational studies of the capsular polysaccharide produced by Neisseria meningitidis group A

(2009) Michela Foschiatti et al.   CARBOHYDRATE RESEARCH

Prevention of meningococcal serogroup C disease by NeisVac-C™

(2009) Ray Borrow et al.   Expert Review of Vaccines

Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs

(2009) Caroline L Trotter et al.   Expert Review of Vaccines

10-valent pneumococcal nontypeableHaemophilus influenzaePD conjugate vaccine: Synflorix™

(2009) Roman Prymula et al.   Expert Review of Vaccines

A Synthetic Carbohydrate-Protein Conjugate Vaccine Candidate against Shigella flexneri 2a Infection

(2009) A. Phalipon et al.   JOURNAL OF IMMUNOLOGY

A Randomized Trial to Determine the Tolerability and Immunogenicity of a Quadrivalent Meningococcal Glycoconjugate Vaccine in Healthy Adolescents

(2009) Lisa A. Jackson et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages

(2009) Michael Bröker et al.   VACCINE

Preparation of bacterial polysaccharide–protein conjugates: Analytical and manufacturing challenges

(2009) Carl E. Frasch   VACCINE

A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children

(2009) M. Knuf et al.   VACCINE

A clinical trial examining the effect of increased total CRM197 carrier protein dose on the antibody response to Haemophilus influenzae type b CRM197 conjugate vaccine

(2008) Vytautas Usonis et al.   VACCINE

Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15–25 years

(2008) Lars Østergaard et al.   VACCINE

Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa

(2008) Che-Hung Lee et al.   VACCINE